Kamp: Supreme Court decision in "pay for delay" case could harm pharma

04/2/2013

Coalition for Healthcare Communication Executive Director John Kamp said in a commentary posted Monday on the Coalition's Website that if the forthcoming decision by the U.S. Supreme Court in FTC v. Actavis regarding AndroGel is decided against the pharmaceuticals industry, it "could create a significant bottom line hit to our business. A decision against pharma would further shorten the patent protection period on many branded drugs." Kamp provided a summary of the important issues at stake in the case, for which oral arguments were heard on March 25. Despite the legal challenges, "don't count the industry out yet," Kamp said. Read more.

View Full Article in:

http://www.cohealthcom.org/2013/04/01/kamp-commentary-supreme-court-decision-cou...

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC